Novartis AG (NYSE:NVS)’s share price gapped up before the market opened on Friday . The stock had previously closed at $77.68, but opened at $78.27. Novartis AG shares last traded at $79.20, with a volume of 967,147 shares traded.

Several research firms recently weighed in on NVS. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Novartis AG in a research report on Wednesday, July 13th. Bank of America Corp. restated a “hold” rating on shares of Novartis AG in a report on Tuesday, July 12th. Zacks Investment Research downgraded Novartis AG from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Argus restated a “hold” rating on shares of Novartis AG in a report on Thursday, August 25th. Finally, TheStreet upgraded Novartis AG from a “hold” rating to a “buy” rating in a report on Friday, June 24th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $91.20.

The firm has a market capitalization of $189.02 billion and a PE ratio of 28.34. The firm’s 50 day moving average price is $81.72 and its 200 day moving average price is $77.68.

Novartis AG (NYSE:NVS) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.05. The business had revenue of $12.47 billion for the quarter, compared to analysts’ expectations of $12.33 billion. During the same quarter in the prior year, the firm posted $1.25 EPS. Equities research analysts forecast that Novartis AG will post $4.73 earnings per share for the current year.

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.